Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 201 - 250 out of 864

Document Document Title
WO/1995/032976A1
Staurosporin derivatives of formula (I), wherein R1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical, R2 is an aliphatic, carbocyclic, carbocycli...  
WO/1995/032974A1
The utility of known and novel staurosporin derivatives of formula (I), wherein R1 is formyl, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is unsubstituted or substituted by aryl, or is an aryl radical; R2 is hydrog...  
WO/1995/032975A1
Staurosporin derivatives of formula (I), wherein R1 is an acyl radical having from 2 to 30 carbon atoms, an aliphatic hydrocarbon radical having up to 29 carbon atoms that is substituted by acyclic substituents, a cycloaliphatic or cyclo...  
WO/1995/029927A2
Glycoconjugate antigens are prepared by preparing a hapten glycoside, especially an alpha glycoside prepared by the Fischer method, with an olefinic aglycon moiety, especially one having a non-terminal double bond, ozonolyzing the hapten...  
WO/1995/015969A1
The present invention consists in methods of preparing sugar derivatives either in isolation or from glycopeptides or glycoproteins. The methods comprise producing sugar hydrazones, sugar pyrazoles, glycosylpyrazones, azoglycan dyes and ...  
WO/1995/007700A1
A method for protecting against mutational damage in mammalian cells induced by irradiation comprising administering a phosphorothioate or phosphorothioate metabolite to the mammal before or up to 3 hours after irradiation.  
WO/1994/021654A1
A process is disclosed for preparing sugar acetals by reacting sugars with ketones in the presence of an acid catalyst. By using an oxonium tetrafluoroborate as acid catalyst, yield and reaction times can be surprisingly improved.  
WO/1994/014827A1
Sulfamate derivatives having formula (I), wherein R1, R2, R3, R4, R5 and R6 are as herein defined, have been found to exhibit anticonvulsant activity and are thus useful in the treatment of conditions such as epilepsy. Further, the prese...  
WO/1994/013685A1
D-psicofuranose and D-psicopyranose derivatives represented by general formulae (I) and (II), useful as the key intermediates in a novel process for producing hydantocidin; wherein R1 through R8 may be the same or different from one anot...  
WO1994004541A3
This invention describes both known and novel compounds, some of which are protein kinase inhibitors, that may be combined with taxol type compounds. The combination of disclosed compounds plus taxol type compounds exhibits powerful syne...  
WO/1994/011381A1
Compounds of this invention are derivatives of pentose monosaccharides which exhibit anti-proliferative and anti-inflammatory activity as well as intermediates for the synthesis of these compounds. Methods of preparation, pharmaceutical ...  
WO/1994/006799A1
A thrombocytopenia remedy containing an indolocarbazole derivative represented by general formula (I) or a pharmacologically acceptable salt thereof as the active ingredient, and a novel indolocarbazole derivative.  
WO/1994/004541A2
This invention describes both known and novel compounds, some of which are protein kinase inhibitors, that may be combined with taxol type compounds. The combination of disclosed compounds plus taxol type compounds exhibits powerful syne...  
WO/1993/018040A1
Compounds are described of formula (I), wherein R1 represents a hydroxyl group or a group selected from -OCOCH=ECHCH(CH3)(CH2)3CH3, -OCOCH=ECHC(CH3)=ECHCH(CH3)CH2CH3 or -OCO-X-CH2CH(CH3)CH2CH3 [where X is -CH=ECHCH(CH3)-, -CH2CH(OH)CH(CH...  
WO/1993/017689A1
A method and pharmaceutical for protecting against genotoxic damage in irradiated cells. Reduction of mutations at the hypoxanthine-guanine phosphoribosyl transferase locus is accomplished by administering an effective dose of a compound...  
WO/1993/018039A1
Compounds are described of formula (I), wherein R1 represents a hydroxyl group or a group selected from -OCOCH=ECHCH(CH3)(CH2)3CH3, -OCOCH=ECHC(CH3)=ECHCH(CH3)CH2CH3 or -OCO-X-CH2CH(CH3)CH2CH3[where X is -CH=ECHCH(CH3)-, -CH2CH(OH)CH(CH3...  
WO/1993/007904A1
Pharmaceutically acceptable compositions of matter comprising a lipophilic oligosaccharide antibiotic, e.g., the everninomicin-type antibiotic of formula (III), at least a stoichiometric amount of a base, e.g., NMG, an amount of, e.g., h...  
WO/1993/006112A1
The present invention relates to an antiviral phosphonate derivate of an acyclic purine nucleoside analog, to pharmaceutically acceptable derivatives thereof and to their use in medical therapy, particularly in the treatment of cytomegal...  
WO1992004359A3
Derivatives of simple monosaccharides which exhibit anti-proliferative and/or anti-inflammatory activity and are useful for treating mammals having inflammatory disorders and/or autoimmune disorders. This invention also encompasses pharm...  
WO/1992/016530A1
Compounds are described of formula (I) wherein R1 represents a hydrogen atom or an acetyl group; R2, R3 and R4 may each independently represent a hydrogen atom or a methyl group; n represents an integer from 1 to 3; and the fluorine atom...  
WO/1992/014745A1
A solvent-free method for synthesizing an ethereally-substituted, blocked monosaccharide comprising the steps of: 1) mixing, in the absence of solvent, a partially blocked monosaccharide unblocked at one position, an alkyl halide or a su...  
WO/1992/012160A1
These compounds inhibit the enzyme squalene synthase and/or are intermediates for the preparation of compounds which inhibit the enzyme squalene synthase. Compounds of the invention may be formulated for use in a variety of conditions wh...  
WO/1992/009276A1
The use of compounds of formula (I) for the treatment of cells having an abnormally elevated cell proliferation, which results in diseases such as psoriasis, inflammatory diseases, rheumatic diseases and allergic dermatologic reactions.  
WO1992005152A3  
WO1991018911A3  
WO/1992/005152A2
A process for converting 1,4- and 1,5-dicarbonyl sugars to pyrrolidine and piperidine amino sugars. Novel compounds resulting from this process are also described.  
WO/1992/004359A2
Derivatives of simple monosaccharides which exhibit anti-proliferative and/or anti-inflammatory activity and are useful for treating mammals having inflammatory disorders and/or autoimmune disorders. This invention also encompasses pharm...  
WO/1992/002525A1
A glucofuranose derivative substituted at the 3,5,6- or 3,6-positions with a radical that provides an anionic charge at physiological pH values is disclosed, as are pharmaceutical compositions, and methods of making and using the same. T...  
WO/1991/019728A1
A nucleotide derivative represented by general formula (I), which has an excellent pharmacological action and is obtained from a structural derivative other than naturally occurring normal cyclic nucleotides: wherein R1 represents hydrog...  
WO/1991/018911A2
This invention relates to a method of producing peracetyloxazolines from peracetyl saccharides. The method involves reacting the starting material, a peracetyl saccharide, with a reagent combination, to directly produce the peracetyl oxa...  
WO/1991/018910A1
A compound of general formula (I), in which each of R1, R2, R3 and R4 independently represent a hydrogen atom or a group -(CO)nR5 in which n is 0 or 1 and R5 represents an alkyl, aryl, cycloalkyl, alkaryl or aralkyl group, or R1 or R2 to...  
WO/1991/002739A1
Methods of stereoselectively preparing a substituted 1,2-anhydrosugar wherein a substituted glycal is converted into a 1,2-anhydrosugar that is utilized to glycosylate a hydroxyl group containing glycal, are disclosed. Methods of prepari...  
WO/1988/000951A1
Method of producing peracetyl oxazolines from peracetyl saccharides. The method involves reacting the starting material, a peracetyl saccharide, with a reactive compound, such as trifilic acid, to directly produce the peracetyl oxazoline.  
WO/1987/006592A1
The preparation method comprises the reaction of an aldose or a polyaldoside in hydrogen fluoride, in the presence of water or not, and is characterized in that the concentration of aldose or polyaldoside in the reaction, calculated when...  
WO1987002366A3  
WO/1987/002366A2
Novel derivatives of the oligosaccharide antibiotic complex 13-384, the derivatives being of general formula (I), wherein R is hydrogen or Z, where Z is a moiety of general formula (II) in which R1 is nitroso, N-hydroxylamino, N-acyl-N-h...  
WO/1987/000529A1
Sugar-containing dipeptides of a new type, their manufacture and use in various pharmaceutical, biological and medical applications, in particular for prophylactic purposes against infections, combating infections diseases of various ori...  
WO/1986/005186A1
Selective esterification of only one of the hydroxy groups in polyols is achieved using an acetalized or a ketalized polyol as the starting material and an enzyme catalysing esterification. Furthermore, the selective esterified polyols m...  
WO/1985/000814A1
The invention relates to a process for the dehydration of glucids, which is applicable to glucids of which the molecule comprises at least one unit of the ketose type, characterized in that the glucid is reacted without addition of water...  
WO/1980/002112A1
Novel heterocyclic anthracycline compounds having antitumor activity against murine P388 leukemia in mice.  
WO/1979/001068A1
Novel arabinofuranosyl nucleosides and nucleotides having 2'-azido, 2'-amino, or 2'-hydrocarbylamino substituents, which have antitumor, antiviral, and antimicrobial properties, are prepared by condensation of a pyrimidine, purine, or 1,...  
WO/1979/001088A1
New glucosamin silyl compounds of formula: (FORMULA) wherein X is a carbonyl group, R1, R4 and R6 a tri-alkyl-lower-sylil group, in particular trimethyl-silyl, R2 is an alkyl group eventually substituted or an aryl carbocylic group, R3 i...  
JP6889232B2
The invention provides methods for the synthesis of eribulin or a pharmaceutically acceptable salt thereof (e.g., eribulin mesylate) through a macrocyclization strategy. The macrocyclization strategy of the present invention involves sub...  
JP2021512046A
The present invention is a novel compound having a tumor vascular remodeling effect and / or anti-CAF (cancer-related fibroblast) activity in an optionally pharmaceutically acceptable carrier (eg, formulas (I), (II)). , (III), (IV) or ph...  
JP2021512066A
Sodium-dependent glucose transporter inhibitors, especially glucopyranosyl derivatives as SGLT1 inhibitors, their pharmaceutically acceptable salts or stereoisomers, their pharmaceutical compositions, and their compounds in the preparati...  
JP6857359B2
There is provided a novel gelator including a sugar derivative. A gelator comprising a compound of Formula (1) or Formula (2):wherein R1 is a linear or branched alkyl group having a carbon atom number of 9 to 20, a cyclic alkyl group hav...  
JP2021508737A
The present invention relates to secondary functional moieties including transition metal based linkers and primary functional moieties attached thereto. The secondary functional moiety according to the present invention comprises a tran...  
JP2021508732A
Provided are compounds of formula (A) used in the prevention or treatment of joint and bone disorders in mammals, such as arthritis and osteoporosis, as well as pharmaceutically acceptable salts and esters thereof, and pharmaceutical com...  
JP2020158489A
To provide a bicyclic ulosonic acid derivative and a method for producing an ulosonic acid derivative, with which the intended bicyclic ulosonic acid derivative and the ulosonic acid derivative of α-form which has a specifically high α...  
JP6761564B2
Provided are an L-proline compound of a sodium-glucose cotransporter 2 inhibitor, and a monohydrate and a crystal of the L-proline compound. Specifically, provided are 1,6-dehydrated-1-C{4-chloro-3-[(3-fluoro-4-ethoxyphenyl)meth yl]pheny...  

Matches 201 - 250 out of 864